Neovacs S.A RSI
Qual é o RSI de Neovacs S.A?
O RSI de Neovacs S.A. é 47.27
Qual é a definição de RSI?
O índice de força relativa (RSI 14) é um indicador de momento que compara a magnitude de ganhos e perdas em um período de tempo especificado para medir a velocidade e a variação dos movimentos de preço de um título.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI de empresas na Setor Health Care em EURONEXT em comparação com Neovacs S.A
O que Neovacs S.A faz?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Empresas com rsi semelhantes a Neovacs S.A
- Latin American Minerals tem RSI de 47.25
- SolarWinds Corp tem RSI de 47.26
- BlackRock Enhanced International Dividend Trust tem RSI de 47.26
- NUGL tem RSI de 47.26
- BioForce Nanosciences tem RSI de 47.26
- Home Bancshares Inc tem RSI de 47.26
- Neovacs S.A tem RSI de 47.27
- KushCo tem RSI de 47.28
- ZK International Co tem RSI de 47.28
- CannaGrow tem RSI de 47.28
- Quantum Corp tem RSI de 47.28
- Canadian Premium Sand tem RSI de 47.28
- Jianpu Technology Inc tem RSI de 47.28